KANABO GROUP PLC Logo

KANABO GROUP PLC

Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.

KNB | IL

Overview

Corporate Details

ISIN(s):
GB00BYQCS703
LEI:
213800XPJFSNWJIYKN52
Country:
United Kingdom
Address:
Churchill House, NW4 4DJ London
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kanabo Group PLC is a medical cannabis and wellness company that develops and distributes cannabis-derived products. The company operates a holistic business model, overseeing the entire product lifecycle from research and development to distribution. Its portfolio includes proprietary THC-based medical formulas targeting conditions like CNS disorders, alongside non-THC CBD products for the consumer wellness market. A key innovation is the VapePod®, a medically certified vaporization device designed for precise, metered-dose delivery of cannabis extracts. Kanabo focuses on creating clinically validated, high-quality formulations and has expanded its offerings to include a digital health platform providing patient access to alternative therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-04 08:00
Business and Financial Review
Revenue Growth, Trading and Operational Update
English 19.6 KB
2025-01-06 08:00
Board/Management Information
Directorate Change
English 11.3 KB
2024-11-19 10:55
Report Publication Announcement
The GP Service Wins Award
English 9.2 KB
2024-10-31 10:48
Director's Dealing
Correction Director/PDMR Shareholding
English 27.2 KB
2024-10-29 12:39
Director's Dealing
Director/PDMR Shareholding
English 26.7 KB
2024-09-30 15:50
Earnings Release
Half-year Report
English 307.5 KB
2024-08-28 15:31
Director's Dealing
Director/PDMR Shareholding
English 35.2 KB
2024-06-27 17:49
Declaration of Voting Results & Voting Rights Announcements
Result of AGM
English 23.0 KB
2024-06-04 08:00
Regulatory News Service
Expansion:14 New Clinics Partnership with Treat-It
English 16.6 KB
2024-05-31 11:30
Pre-Annual General Meeting Information
Notice of AGM
English 12.0 KB
2024-04-30 15:15
Annual Report
Annual Financial Report
English 895.4 KB
2024-03-28 08:00
Business and Financial Review
Expansion of Treat It to Mental Health Treatments
English 14.0 KB
2024-03-27 18:11
Major Shareholding Notification
Holding(s) in Company
English 24.2 KB
2024-03-25 08:00
Legal Proceedings Report
Germany Medical Cannabis Legislation Reform
English 14.0 KB
2024-03-18 10:14
Regulatory News Service
Agritec Update
English 13.9 KB

Automate Your Workflow. Get a real-time feed of all KANABO GROUP PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KANABO GROUP PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KANABO GROUP PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.